

Date: 14th August, 2023

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
P.J Towers, Dalal Street,
Mumbai 400001
Script Code: 540359

Dear Sirs,

Sub: Outcome of Board Meeting.

Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. August 14, 2023 inter alia has considered and approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2023. The same has also been reviewed by the Audit Committee in its meeting held today.

Further B A Shah S R Mehta & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter ended June 30, 2023 and the Board has also taken on record their Limited Review Report on the said Results.

A copy of the Limited Review Report along with the Financial Results is enclosed herewith. The Meeting of the Board of Directors commenced at 04:30 PM and concluded at 07: 30 PM.

You are requested to kindly take the above information on your record.

Thanking you.

Yours faithfully,

For Parmax Pharma Limited



Yash Vora
Company Secretary

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

Statement of Standalone Unaudited Results for the Quarter ended 30.06.2023

					(in Rs.Thousands)	
Sr. No.	Particulars	Quarter Ended (30.06.2023)	Preceding Quarter ended (31.03.2023)	Corresponding Quarter Ended (30.06.2022)	Previous year ended (31.03.2023)	
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1	Income from Operations					
	(a) Revenue from operations	14001.43	63819.33	15553.55	154243.45	
	(b) Other income	136.95	149.15	84.00	397.21	
	Total income from operations (net) (a+b)	14138.38	63968.48	15637.56	154640.66	
2	Expenses					
	(a) Cost of materials consumed	2827.89	-9497.7	12801.91	55136.35	
	(b) Purchase of stock-in-trade	0	0	0.00	0.00	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1460.76	45473.8	-7995.62	-210.00	
	(d) Employee benefits expense	7249.92	6011.77	5481.06	28017.97	
	(e) Finance Costs	1217.14	542.61	914.05	3690.54	
	(f) Depreciation and amortisation expense	4187.81	4728.76	4614.08	18785.72	
	(g) Other expenses*	8983.79	13477.73	13002.97	48758.86	
	Total expenses	25927.32	60736.97	28818.45	154179.43	
3	Profit/(Loss) from operations before exceptional items and tax (1-2)	-11788.94	3231.51	-13180.89	461.23	
4	Exceptional Items	0	0	0	0	
5	Profit/ (Loss) before tax (3-4)	-11788.94	3231.51	-13180.89	461.23	
6	Tax expense:					
	(1) Current tax	0	1850.00	0	1850.00	
	(2) Deferred tax	0	348.09	0	348.09	
7	Net Profit / (Loss) for the period from continuing operations (5-6)	-11788.94	1729.60	-13180.89	-1040.68	
8	Profit/(loss) from discontinuing operations					
9	Tax expense of discontinuing operations	0	0	0	0	
10	Profit/(loss) from Discontinuing operations (after tax) (8-9)					
11	Profit (Loss) for the period (7+10)	-11788.94	1729.60	-13180.89	-1040.68	
12	Other Comprehensive Income		0	0	0	
13	Total Comprehensive Income for the period (11+12) Comprising Profit (Loss) and Other comprehensive Income for the period)	-11788.94	1729.60	-13180.89	-1040.68	
14	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	
15	Earnings per share (for continuing operation) (of Rs. 10/- each) (not annualised):					
	(a) Basic	-3.15	0.46	-3.52	-0.28	
	(b) Diluted	-	-	-	-	

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)



Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th August, 2023.
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2023.
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter ended 30th June, 2023 in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED

U. Gosalia

Dr. Umang Alkesh Gosalia
Managing Director



Place Hadamtala (Rajkot)
Date: 14.08.2023

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Billipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended **30th June 2023** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14th August 2023**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there

Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com



B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 14.08.2023

For **B. A. SHAH S R MEHTA & Co.**

Chartered Accountants

FRN NO : 128796W



Malay B Shah

MALAY B SHAH

Partner

M. No. 159526

UDIN : 23159526BGYP6829

Head Office:

209-Sapphire Complex, IInd Floor

21/25-B New Jagnath Plot,

Dr. Yagnik Road

RAJKOT- 360 001

(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149

(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com